Overview of Dr. Seidman
Dr. Andrew Seidman is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 37 years. Dr. Seidman accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
- Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1985 - 1988
- Drexel University College of MedicineClass of 1985
Certifications & Licensure
- NY State Medical License 1989 - 2026
- NJ State Medical License 2020 - 2025
- FL State Medical License 2019 - 2021
- PA State Medical License 1986 - 1990
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic Start of enrollment: 1998 Jul 01
- Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer Start of enrollment: 1998 Apr 01
- Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 2000 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 98 citationsA phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effectsGary Deng, Hong Lin, Andrew D. Seidman, Monica Fornier, Gabriella D'Andrea
Journal of Cancer Research and Clinical Oncology. 2009-03-01 - 127 citationsCapecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.Aki Morikawa, David M. Peereboom, Helen R. Thorsheim, Ramakrishna Samala, Rajiv Balyan
Neuro-Oncology. 2015-02-01 - 148 citationsProspective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.Peter A. Forsyth, Casilda Balmaceda, Kendra Peterson, Andrew D. Seidman, Penny M. A. Brasher
Journal of Neuro-Oncology. 1997-10-01
Authored Content
- A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer PatientsAugust 2018
Press Mentions
- Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)December 11th, 2020
- Odonate Therapeutics Announces Positive Top-Line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast CancerAugust 24th, 2020
- Selected Abstracts from the San Antonio Breast Cancer SymposiumFebruary 11th, 2019
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: